IL308225A - Combination therapies that include SHP2 inhibitors and EGFR tyrosine kinase inhibitors - Google Patents

Combination therapies that include SHP2 inhibitors and EGFR tyrosine kinase inhibitors

Info

Publication number
IL308225A
IL308225A IL308225A IL30822523A IL308225A IL 308225 A IL308225 A IL 308225A IL 308225 A IL308225 A IL 308225A IL 30822523 A IL30822523 A IL 30822523A IL 308225 A IL308225 A IL 308225A
Authority
IL
Israel
Prior art keywords
inhibitors
tyrosine kinase
combination therapies
egfr tyrosine
shp2
Prior art date
Application number
IL308225A
Other languages
English (en)
Hebrew (he)
Inventor
Farbod Shojaei
Jill M Ricono
Robert Goodenow
Mireille Gillings
Original Assignee
Huyabio Int Llc
Farbod Shojaei
Jill M Ricono
Robert Goodenow
Mireille Gillings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huyabio Int Llc, Farbod Shojaei, Jill M Ricono, Robert Goodenow, Mireille Gillings filed Critical Huyabio Int Llc
Publication of IL308225A publication Critical patent/IL308225A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL308225A 2021-05-05 2022-05-04 Combination therapies that include SHP2 inhibitors and EGFR tyrosine kinase inhibitors IL308225A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163184697P 2021-05-05 2021-05-05
US202263320991P 2022-03-17 2022-03-17
PCT/US2022/027693 WO2022235815A1 (en) 2021-05-05 2022-05-04 Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
IL308225A true IL308225A (en) 2024-01-01

Family

ID=83932546

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308225A IL308225A (en) 2021-05-05 2022-05-04 Combination therapies that include SHP2 inhibitors and EGFR tyrosine kinase inhibitors

Country Status (8)

Country Link
US (1) US20220370456A1 (cg-RX-API-DMAC10.html)
EP (1) EP4334317A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024516998A (cg-RX-API-DMAC10.html)
AU (1) AU2022270106A1 (cg-RX-API-DMAC10.html)
CA (1) CA3217092A1 (cg-RX-API-DMAC10.html)
IL (1) IL308225A (cg-RX-API-DMAC10.html)
MX (1) MX2023012929A (cg-RX-API-DMAC10.html)
WO (1) WO2022235815A1 (cg-RX-API-DMAC10.html)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
WO2015050345A1 (en) 2013-10-01 2015-04-09 Lg Electronics Inc. Control apparatus for mobile terminal and control method thereof
PT3468972T (pt) 2016-06-14 2020-08-21 Novartis Ag Compostos e composições para inibir a atividade da shp2
CN110730678B (zh) * 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
CN117263942A (zh) * 2018-03-21 2023-12-22 传达治疗有限公司 Shp2磷酸酶抑制剂及其使用方法
CN111647000B (zh) * 2019-03-04 2021-10-12 勤浩医药(苏州)有限公司 吡嗪类衍生物及其在抑制shp2中的应用
US11033547B2 (en) * 2019-03-07 2021-06-15 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as SHP2 antagonists
EP4288057A4 (en) * 2021-02-05 2025-03-12 Verastem, Inc. Combination therapy for treating abnormal cell growth
WO2022235822A1 (en) * 2021-05-05 2022-11-10 Huabio International, Llc Shp2 inhibitor monotherapy and uses thereof
CA3217084A1 (en) * 2021-05-05 2022-11-10 Farbod Shojaei Combination therapies comprising shp2 inhibitors and pd-1 inhibitors

Also Published As

Publication number Publication date
AU2022270106A1 (en) 2023-12-14
US20220370456A1 (en) 2022-11-24
WO2022235815A1 (en) 2022-11-10
EP4334317A4 (en) 2025-03-05
CA3217092A1 (en) 2022-11-10
MX2023012929A (es) 2023-11-13
EP4334317A1 (en) 2024-03-13
JP2024516998A (ja) 2024-04-18

Similar Documents

Publication Publication Date Title
SG11202109067PA (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
IL281805A (en) Quinazoline derivatives as tyrosine kinase inhibitors, preparations, methods for their preparation and use
PT3911648T (pt) 6¿-[[(1s,3s)-3-[[5-(difluorometoxi)-2-pirimidinil]amino]ciclopentil]amino][1(2h),3¿-bipiridina]-2-ona como inibidor de pcsk9 e seus métodos de utilização
EP3906061A4 (en) METHODS OF TREATMENT OF CANCER USING COMBINATIONS OF PARP INHIBITORS AND ANTIBODY RADIOCONJUGATE
IL300107A (en) HSD17B13 quinazolinone inhibitors and uses thereof
SG11202012820PA (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
GB2591931B (en) Systems and methods for privacy preserving determination of intersections of sets of user identifiers
IL283599A (en) Tyrosine kinase inhibitors, preparations and methods
IL308234A (en) Monotherapy with an SHP2 inhibitor and its uses
ZA201908392B (en) Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor
IL272369A (en) Therapeutic combination of a third generation EGFR tyrosine kinase inhibitor and a CYCLIN D KINASE inhibitor
IL286983A (en) Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor
PL3972603T3 (pl) Sposoby leczenia zespołu sjögrena przy użyciu inhibitora kinazy tyrozynowej brutona
PL3902548T3 (pl) Inhibitor egfr z powodującą oporność na leczenie mutacją l718 i/lub l792 do stosowania w leczeniu nowotworu
ZA202200268B (en) Combination therapy of gpr119 agonists and dpp-4 inhibitors
SG11202112412QA (en) Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
ZA202200834B (en) Isoquinolinone derivatives serving as rock protein kinase inhibitors and use thereof
IL255582A (en) Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
IL315848A (en) Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment
EP3999064A4 (en) Inhibitors of tyrosine kinase
EP4097140A4 (en) USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS TO TREAT CANCERS WITH NRG1 GENE FUSIONS
EP3872072A4 (en) CRYSTALLINE FORM OF TYROSINE KINASE INHIBITOR MALEATE AND METHOD FOR PREPARING IT
IL315365A (en) Spleen tyrosine kinase inhibitor, composition and methods of use
ES3065589T3 (en) Tyrosine kinase inhibitors
EP4334317A4 (en) COMBINATION THERAPIES WITH SHP2 INHIBITORS AND EGFR TYROSINE KINAS INHIBITORS